Sort
16,179 grants matching “malaria”
Impact of gene-drive systems for population modification on malaria vector mosquitoes
$1,030,493Anthony A James · University Of California-Irvine · R01 · FY2025 · AI
Center for the Study of Complex Malaria in India
$1,030,435Jane Carlton · New York University · U19 · FY2022 · AI
Core 3: Biocontainment Research Support Services Core
$1,029,538Colin S. Duckett · Duke University · UC7 · FY2023 · AI
Clinical and translational evaluation of vaccination strategies for Zika, Chikungunya, Dengue, Leishmania, Malaria, and other important or emerging vector-borne diseases
$1,029,125Matthew Memoli · National Institute Of Allergy And Infectious Diseases · ZIA · FY2023 · AI
Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure
$1,028,550Brandon Keith Wilder · Oregon Health & Science University · U01 · FY2022 · AI
Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure
$1,028,550Brandon Keith Wilder · Oregon Health & Science University · U01 · FY2023 · AI
Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure
$1,028,550Brandon Keith Wilder · Oregon Health & Science University · U01 · FY2024 · AI
Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure
$1,028,550Brandon Keith Wilder · Oregon Health & Science University · U01 · FY2025 · AI
Malaria Vaccines: CSP-rEPA/ALHYDROGEL
$1,028,315Louis Miller · Niaid Extramural Activities · Z01 · FY2007 · AI
Malaria Vaccines: AMA1-C2/ALHYDROGEL + CPG 7909
$1,028,315Louis Miller · Niaid Extramural Activities · Z01 · FY2007 · AI
Malaria Vaccines: Pfs25-Pfs25/ALHYDROGEL
$1,028,315Louis Miller · Niaid Extramural Activities · Z01 · FY2007 · AI
UCSF HIV Clinical Trials Unit
$1,028,280Diane V Havlir · University Of California, San Francisco · U01 · FY2008 · AI
Malaria Parasite Ligands And Host Cell Receptors
$1,027,546Louis Miller · National Institute Of Allergy And Infectious Diseases · ZIA · FY2017 · AI
University of Rochester Vaccine and Treatment Evaluation Unit (VTEU)
$1,026,345Ann R Falsey · University Of Rochester · UM1 · FY2023 · AI
Malaria Transmission Blocking Vaccine Discovery
$1,025,407Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Development of Pre-Erythrocytic Malaria Vaccines
$1,024,485Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Genomic Studies of the Impact of External Factors on Parasite Development and Disease Outcome
$1,024,222Joana Carneiro Da Silva · University Of Maryland Baltimore · U19 · FY2019 · AI
Inhibition of Malaria Chloroquine Resistance Transporters
$1,023,775M.g. Finn · Scripps Research Institute, The · R56 · FY2010 · AI
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease
$1,023,525Swee Lay Thein · National Heart, Lung, And Blood Institute · ZIA · FY2019 · HL
Project A: Epidemiology of Drug Resistance
$1,021,405Pradipsinh K. Rathod · University Of Washington · U19 · FY2019 · AI
PROTOZOAN PURINE PHOSPHORIBOSYLTRANSFERASES AS TARGETS TO TREAT MALARIA, AFRICAN TRYPANOSOMIASIS AND CHAGAS'S DISEASE
$1,020,767Thomas Meek · Texas A&M Agrilife Research · R01 · FY2020 · AI
MIT Laser Biomedical Research Center (P41-RR02594)
$1,019,231Peter T. So · Massachusetts Institute Of Technology · P41 · FY2014 · EB
UCSF HIV Clinical Trials Unit
$1,018,836Diane V Havlir · University Of California, San Francisco · U01 · FY2009 · AI
USING VACSIM DELIVERY TO ENHANCE MALARIA VACCINE EFFICACY
$1,017,297University Of Georgia Research Foundation, Inc. · · FY2016 · Department of the Army
AWI-Gen Phase 2: Genomic and environmental risk factors for cardiometabolic disease in Africans
$1,017,000Michele Michele Ramsay · Wits Health Consortium (Pty), Ltd · U54 · FY2022 · HG